Hims & Hers Expands Into Lab Testing to Boost Preventive Care
Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion.
/ 12 items
#HIMS↓
Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.
Hims & Hers Shares Jump on Talks With Novo Nordisk, Strong Q3 Results
Hims & Hers Health rose in after-hours trading after revealing talks with Novo Nordisk about offering Wegovy’s new obesity pill. The telehealth firm also beat Q3 revenue estimates, reporting nearly $600 million in sales and strong subscriber growth.
Trump Vows Sharp Cut to Ozempic Price, Sending Novo Nordisk Shares Tumbling
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Hers Launches Specialized Menopause and Perimenopause Care to Close Major Healthcare Gap
Hers launched specialty care for menopause/perimenopause, offering women personalized plans including prescription pills, patches, or creams.
BofA Slashes Hims & Hers Q4 Forecast 6.5% Below Street
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.